March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
1 citations,
April 2023 in “Frontiers in Immunology” New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.
[object Object] May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
6 citations,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
88 citations,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
4 citations,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
2 citations,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
159 citations,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
3 citations,
November 2021 in “Journal of The American Academy of Dermatology” Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
42 citations,
April 2021 in “JCI insight” Blocking JAK3 signaling can reverse hair loss from alopecia areata.
[object Object] August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
3 citations,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
1 citations,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
January 2025 in “Frontiers in Medicine” Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.
November 2023 in “Translational Medicine Communications” Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.
27 citations,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.